CN106659763A - 使用nmda调节剂治疗抑郁症的方法 - Google Patents

使用nmda调节剂治疗抑郁症的方法 Download PDF

Info

Publication number
CN106659763A
CN106659763A CN201580043626.3A CN201580043626A CN106659763A CN 106659763 A CN106659763 A CN 106659763A CN 201580043626 A CN201580043626 A CN 201580043626A CN 106659763 A CN106659763 A CN 106659763A
Authority
CN
China
Prior art keywords
patient
weeks
depression
glyx
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580043626.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·伯奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naurex Inc
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of CN106659763A publication Critical patent/CN106659763A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201580043626.3A 2014-08-14 2015-08-13 使用nmda调节剂治疗抑郁症的方法 Pending CN106659763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037374P 2014-08-14 2014-08-14
US62/037,374 2014-08-14
PCT/US2015/045071 WO2016025721A1 (en) 2014-08-14 2015-08-13 Methods of treating depression using nmda modulators

Publications (1)

Publication Number Publication Date
CN106659763A true CN106659763A (zh) 2017-05-10

Family

ID=55304631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580043626.3A Pending CN106659763A (zh) 2014-08-14 2015-08-13 使用nmda调节剂治疗抑郁症的方法

Country Status (18)

Country Link
US (1) US20170296616A1 (enExample)
EP (1) EP3180015A4 (enExample)
JP (2) JP2017524721A (enExample)
KR (1) KR20170040351A (enExample)
CN (1) CN106659763A (enExample)
AU (2) AU2015301650A1 (enExample)
BR (1) BR112017002930A2 (enExample)
CA (1) CA2957937A1 (enExample)
CL (1) CL2017000378A1 (enExample)
CO (1) CO2017002356A2 (enExample)
IL (1) IL250557A0 (enExample)
MX (1) MX2017002052A (enExample)
PH (1) PH12017500275A1 (enExample)
RU (1) RU2017107033A (enExample)
SG (2) SG10201810016XA (enExample)
UA (1) UA123623C2 (enExample)
WO (1) WO2016025721A1 (enExample)
ZA (1) ZA201701526B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111670041A (zh) * 2017-12-05 2020-09-15 诺雷克斯股份有限公司 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180102052A (ko) * 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
US11358935B2 (en) 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
JP2021512857A (ja) * 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRYSTAL JOHN等: "Rapid-acting glutamatergic antidepressants:the path to keatmine and beyond", 《BIOLOGICAL PSYCHIATRY》 *
MESSNER M.等: "Maintenance keatmine treatment produces long-term recovery from depression", 《PRIMARY PSYCHIATRY》 *
MOSKAL JR.等: "GLYX-13，an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111670041A (zh) * 2017-12-05 2020-09-15 诺雷克斯股份有限公司 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合

Also Published As

Publication number Publication date
CO2017002356A2 (es) 2017-06-09
RU2017107033A (ru) 2018-09-14
IL250557A0 (en) 2017-03-30
MX2017002052A (es) 2018-08-15
SG10201810016XA (en) 2018-12-28
ZA201701526B (en) 2018-05-30
CA2957937A1 (en) 2016-02-18
CL2017000378A1 (es) 2017-11-03
RU2017107033A3 (enExample) 2019-02-12
AU2015301650A1 (en) 2017-03-23
JP2017524721A (ja) 2017-08-31
PH12017500275A1 (en) 2017-07-03
WO2016025721A1 (en) 2016-02-18
EP3180015A4 (en) 2018-02-14
UA123623C2 (uk) 2021-05-05
BR112017002930A2 (pt) 2017-12-05
US20170296616A1 (en) 2017-10-19
JP2020128391A (ja) 2020-08-27
EP3180015A1 (en) 2017-06-21
SG11201701134XA (en) 2017-03-30
KR20170040351A (ko) 2017-04-12
AU2020203165A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
CN106659763A (zh) 使用nmda调节剂治疗抑郁症的方法
Mitchell et al. Good night and good luck: norepinephrine in sleep pharmacology
JP6329140B2 (ja) ブレクスピプラゾール又はその塩を含有する神経変性疾患に伴う周辺症状又は精神疾患に伴う衝動性症状の予防及び／又は治療剤
ES2742728T3 (es) Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
JP2023011027A (ja) Ｒ－ケタミンおよびその塩の医薬品としての応用
EP2485751B1 (en) GLYX-13 for use in a method of treating refractory depression
JP4993523B2 (ja) ２０（ｓ）−プロトパナキサジオールの抗うつ薬製造への使用
CN108420819A (zh) 用于治疗神经障碍的新组合物
KR20140136982A (ko) 치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
CN101977606A (zh) 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法
ES2970059T3 (es) Método de tratamiento del síndrome de Prader-Willi
EP2510949A1 (en) Therapeutic agent for fibromyalgia
ES2805448T3 (es) Benzazepinas fusionadas para el tratamiento de la tartamudez
JP2023505155A (ja) 神経変性疾患に関連する認知障害を治療する方法
CN102014931B (zh) 芍药甙的抗抑郁症用途、制备方法及其药物组合物
Zhang et al. Electroacupuncture alleviates affective pain in an inflammatory pain rat model
ES2914043T3 (es) Benzazepinas condensadas para el tratamiento del síndrome de tourette
CN103157111B (zh) 新组合以及含有其的药物组合物
ES2662570T3 (es) Composición para tratar el trastorno de deseo sexual hipoactivo
CN102858176A (zh) 镇痛化合物、组合物及其应用
Zhang et al. Acupuncture alleviates the affective dimension of pain in a rat model of inflammatory hyperalgesia
CN113694055B (zh) 沉香四醇在制备治疗血管性痴呆疾病的药物中的应用
CN105832724A (zh) 吲哚醇在制备抗抑郁症药物中的用途
CN106102762A (zh) 治疗脑部病症或鉴定与其相关的生物标记的方法
CN112569237B (zh) 伊马替尼及其衍生物与尼古丁或其类似物联用或复方在防治尼古丁成瘾与复吸中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20170510

RJ01 Rejection of invention patent application after publication